Fineline Cube

Follow:
14398 Articles
Aficamten Market Filing Accepted by China’s CDE for Hypertrophic Cardiomyopathy Treatment
CompanyDrug

Aficamten Market Filing Accepted by China’s CDE for Hypertrophic Cardiomyopathy Treatment

Jiangsu Hengrui’s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication
CompanyDrug

Jiangsu Hengrui’s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication

Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer
CompanyDrug

Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer

Boehringer Ingelheim Partners with Circle Pharma to Develop First-in-Class Cyclin Inhibitor
CompanyDeals

Boehringer Ingelheim Partners with Circle Pharma to Develop First-in-Class Cyclin Inhibitor

TenNor Therapeutics Secures USD 42.16 Million in Series E Financing for Antibacterial Pipeline
CompanyDeals

TenNor Therapeutics Secures USD 42.16 Million in Series E Financing for Antibacterial Pipeline

Huadong Medicine Gets NMPA Green Light for BCMA-Targeted ADC HDM2027 Phase I/IIa Study
CompanyDrug

Huadong Medicine Gets NMPA Green Light for BCMA-Targeted ADC HDM2027 Phase I/IIa Study

Lepu Medical Receives Approval for Noninvasive Blood Glucose Meter NeoGlu 01 in China
CompanyMedical Device

Lepu Medical Receives Approval for Noninvasive Blood Glucose Meter NeoGlu 01 in China

Leqembi, Alzheimer’s Drug by Eisai and Biogen, Now Covered by Qihuibao Insurance in China
CompanyDrug

Leqembi, Alzheimer’s Drug by Eisai and Biogen, Now Covered by Qihuibao Insurance in China

Bayer AG and Meituan Deepen Partnership to Transform Skin Health Market in China
CompanyDeals

Bayer AG and Meituan Deepen Partnership to Transform Skin Health Market in China

Changchun High & New Technology Industries Receives FDA Tacit Approval for GenSci122 Clinical Study
CompanyDrug

Changchun High & New Technology Industries Receives FDA Tacit Approval for GenSci122 Clinical Study

Jiangsu Hengrui Medicine Co., Ltd (600276.SH), a leading pharmaceutical company in China, has announced that it has received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA) for its modified drug HR19042, which targets active autoimmune hepatitis (AIH).
CompanyDrug

Jiangsu Hengrui’s HR19042 Earns Breakthrough Designation for Autoimmune Hepatitis Treatment in China

Eli Lilly’s Mirikizumab Shows Statistically Significant Improvement in Crohn's Disease VIVID-1 Study
CompanyDrug

Eli Lilly’s Mirikizumab Shows Statistically Significant Improvement in Crohn’s Disease VIVID-1 Study